 TEL AVIV, Israel, Sept. 17, 2021 GLOBE NEWSWIRE -- VBL Therapeutics NASDAQ: VBLT today announced that the independent Data Safety Monitoring Committee DSMC of the ongoing OVAL Phase 3 registration-enabling study of VB-111 in ovarian cancer has conducted its fifth pre-planned review and has provided clearance to proceed with further clinical research as planned with no changes to the protocol. 